1. Home
  2. LAC vs COLL Comparison

LAC vs COLL Comparison

Compare LAC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lithium Americas Corp.

LAC

Lithium Americas Corp.

HOLD

Current Price

$5.16

Market Cap

1.4B

ML Signal

HOLD

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$48.67

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAC
COLL
Founded
2023
2002
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
LAC
COLL
Price
$5.16
$48.67
Analyst Decision
Hold
Strong Buy
Analyst Count
7
6
Target Price
$5.50
$47.50
AVG Volume (30 Days)
14.5M
515.8K
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.63
Revenue
N/A
$757,067,000.00
Revenue This Year
N/A
$26.35
Revenue Next Year
N/A
$3.67
P/E Ratio
N/A
$29.92
Revenue Growth
N/A
26.34
52 Week Low
$2.31
$23.23
52 Week High
$10.52
$49.16

Technical Indicators

Market Signals
Indicator
LAC
COLL
Relative Strength Index (RSI) 47.43 70.71
Support Level $5.12 $46.15
Resistance Level $5.61 $49.16
Average True Range (ATR) 0.31 1.32
MACD 0.04 -0.16
Stochastic Oscillator 51.60 92.11

Price Performance

Historical Comparison
LAC
COLL

About LAC Lithium Americas Corp.

Lithium Americas is a pure-play lithium producer. Following a deal with the US government, the firm will own 59% of one resource, Thacker Pass, which is located in northwest Nevada, with automaker General Motors owning 36% and the US government owning 5%. Thacker Pass is under construction and expected to begin production in 2028. Thacker Pass is one of the largest known lithium resources in the world. The project would be the first clay-based asset to enter production, and we estimate it will be in bottom half of the global cost curve. Management plans to develop Thacker Pass into a fully integrated lithium production site, with downstream refining capabilities on site, and will sell into the lithium chemical market.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: